GlassScriptPhysician profile
Matthew Exum
NPI 1326519026
$732.59
in general payments reported to CMS, 2019-2025
8 companies · $19.66 in 2025
The $19.66 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.13 · 2022: $568 · 2023: $95.61 · 2025: $19.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $79.75 · Food and Beverage: $35.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $79.75 |
| Food and Beverage | $35.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $274.02 | 2022 | |
| Genzyme Corporation | $121.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.77 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $87.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.75 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $22.80 | 2022 | |
| Abbvie INC. | $19.66 | 2025 | |
| Amgen INC. | $15.86 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Exum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.